PL2856152T3 - Nowe biomarkery do szacowania ryzyka niewydolności przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu narządu - Google Patents

Nowe biomarkery do szacowania ryzyka niewydolności przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu narządu

Info

Publication number
PL2856152T3
PL2856152T3 PL13729629T PL13729629T PL2856152T3 PL 2856152 T3 PL2856152 T3 PL 2856152T3 PL 13729629 T PL13729629 T PL 13729629T PL 13729629 T PL13729629 T PL 13729629T PL 2856152 T3 PL2856152 T3 PL 2856152T3
Authority
PL
Poland
Prior art keywords
estimate
risk
organ transplantation
new biomarkers
patient mortality
Prior art date
Application number
PL13729629T
Other languages
English (en)
Inventor
Cornelis Vermeer
Martin DE BORST
Original Assignee
Nattopharma Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nattopharma Asa filed Critical Nattopharma Asa
Publication of PL2856152T3 publication Critical patent/PL2856152T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/10Post-translational modifications [PTMs] in chemical analysis of biological material acylation, e.g. acetylation, formylation, lipoylation, myristoylation, palmitoylation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
PL13729629T 2012-06-04 2013-06-04 Nowe biomarkery do szacowania ryzyka niewydolności przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu narządu PL2856152T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12170756.6A EP2671574A1 (en) 2012-06-04 2012-06-04 Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation
EP13729629.9A EP2856152B1 (en) 2012-06-04 2013-06-04 New biomarkers to estimate the risk of allograft failure and patient mortality after organ transplantation
PCT/EP2013/061519 WO2013182579A1 (en) 2012-06-04 2013-06-04 New biomarkers to estimate the risk of allograft failure and patient mortality after organ transplantation

Publications (1)

Publication Number Publication Date
PL2856152T3 true PL2856152T3 (pl) 2022-02-07

Family

ID=48651994

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13729628.1T PL2854788T3 (pl) 2012-06-04 2013-06-04 Zastosowanie witaminy K do zmniejszenia niepowodzenia przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu nerki
PL13729629T PL2856152T3 (pl) 2012-06-04 2013-06-04 Nowe biomarkery do szacowania ryzyka niewydolności przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu narządu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13729628.1T PL2854788T3 (pl) 2012-06-04 2013-06-04 Zastosowanie witaminy K do zmniejszenia niepowodzenia przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu nerki

Country Status (11)

Country Link
US (2) US20150141386A1 (pl)
EP (3) EP2671574A1 (pl)
DK (1) DK2856152T3 (pl)
ES (1) ES2891249T3 (pl)
HR (1) HRP20211676T1 (pl)
HU (1) HUE056601T2 (pl)
LT (1) LT2856152T (pl)
PL (2) PL2854788T3 (pl)
PT (1) PT2856152T (pl)
SI (1) SI2856152T1 (pl)
WO (2) WO2013182579A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635478A (en) * 1989-09-18 1997-06-03 Yale University Use of calcitonin gene-related peptide to regulate immune response
WO2000008495A2 (en) * 1998-08-06 2000-02-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Antiproliferative naphthoquinones, derivatives, compositions, and uses thereof
US7700296B2 (en) 1999-07-04 2010-04-20 Mgp Diagnostics As Diagnostic assay for human Matrix Gla-protein and its use as a biomarker
AU6688700A (en) 1999-07-04 2001-01-22 Cardiovascular Research Institute Maastricht (Carim) Diagnostic assay for human matrix gla-protein and its use as a biomarker
DK1153548T3 (da) 2000-05-12 2007-09-10 Nattopharma Asa Levnedsmiddelprodukt, der indeholder vitamin k2
WO2004108748A2 (en) * 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
WO2005054503A2 (en) * 2003-12-03 2005-06-16 Novartis Ag Biomarkers for graft rejection
WO2005107731A1 (ja) * 2004-05-12 2005-11-17 Eisai R & D Management Co., Ltd. ビタミンk2を有効成分として含む治療剤
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
US20110300142A1 (en) * 2007-05-25 2011-12-08 Salford Leif G Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
WO2012012370A1 (en) * 2010-07-19 2012-01-26 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease

Also Published As

Publication number Publication date
PT2856152T (pt) 2021-09-29
ES2891249T3 (es) 2022-01-26
WO2013182578A1 (en) 2013-12-12
EP2854788A1 (en) 2015-04-08
US20150141386A1 (en) 2015-05-21
EP2856152B1 (en) 2021-08-04
HUE056601T2 (hu) 2022-02-28
EP2854788B1 (en) 2024-12-18
DK2856152T3 (da) 2021-11-01
HRP20211676T1 (hr) 2022-02-18
EP2671574A1 (en) 2013-12-11
US20150153352A1 (en) 2015-06-04
LT2856152T (lt) 2021-12-10
EP2856152A1 (en) 2015-04-08
WO2013182579A1 (en) 2013-12-12
EP2854788C0 (en) 2024-12-18
PL2854788T3 (pl) 2025-02-24
SI2856152T1 (sl) 2022-01-31

Similar Documents

Publication Publication Date Title
IL242804B (en) Pridopidine to reduce functional decline in Huntington's patients
DK4233795T3 (da) Hjerteklapprotese
EP2856972A4 (en) ARTIFICIAL HEARTLAP
IL235285B (en) Heart valve prosthesis
EP2568924A4 (en) HEART VALVE PROSTHESIS
PT3527584T (pt) Recetores de célula t anti-ny-eso-1 murinos
BR112015007861A2 (pt) prótese de tecido
SG11201501558RA (en) Method for maintaining organ or tissue for transplantation use for long period
EP2990010A4 (en) ARTIFICIAL BLOOD VESSEL
DK2952577T3 (da) Fremgangsmåde til at separere celle fra biologisk væv
DK2735290T3 (da) Protese eller ortose
SG11201502214PA (en) Adipose tissue cells
HUE042708T2 (hu) Szívelégtelenség diagnosztika
GB201421052D0 (en) Artificial tissue
PL2856152T3 (pl) Nowe biomarkery do szacowania ryzyka niewydolności przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu narządu
GB201219707D0 (en) In situ cardiac tissue engineering
DK2735291T3 (da) Protese eller ortose
GB201011931D0 (en) Double quick stick
GB201216933D0 (en) Adipose tissue cells
GB201216936D0 (en) Adipose tissue cells
DK3494928T3 (da) Hjerteklapprotese
HU1000541D0 (en) Reserve staff
ES1094231Y (es) Cabina piramidal para equilibrar la bioenergía del cuerpo humano
GB201309908D0 (en) Co-gro:The manipulation of living plant life for structural purposes
TWM475181U (en) Structure of shoesole